Serum miRNA Profiling for Early PDAC Diagnosis and Prognosis: A Retrospective Study

Area of Science:

• Oncology
• Molecular Biology
• Biomarker Discovery

Background:

• Pancreatic ductal adenocarcinoma (PDAC) prognosis is stage-dependent, yet survival varies in early-stage disease.
• Circulating microRNAs (miRNAs) show promise as biomarkers for PDAC prognosis.
• Early-stage PDAC patient survival prediction using serum miRNA signatures requires further investigation.

Purpose of the Study:

• To identify serum miRNA signatures that predict survival in early-stage pancreatic cancer patients.
• To explore the potential of miRNAs as prognostic biomarkers for PDAC.
• To differentiate between prolonged and short survival groups in early-stage PDAC.

Main Methods:

• Serum RNA expression profiling using Agilent microarrays on 15 early-stage PDAC patients and 4 controls.
• Classification of PDAC patients into short (<14 months) and long (>22 months) survival groups.
• Bioinformatic analysis including Significance Analysis of Microarray (SAM), binary logistic regression, and ROC analyses.

Main Results:

• 76 differentially expressed miRNAs were identified between PDAC patients and controls, with most downregulated in PDAC.
• Six miRNAs were independently correlated with early PDAC, with hsa-miR-6821-5p showing the best diagnostic ROC curve.
• Specific miRNAs (hsa-miR-3135b, hsa-miR-6126, hsa-miR-486-5p) differentiated survival groups, and hsa-miR-4516 emerged as an independent survival predictor targeting cancer pathways.

Conclusions:

• Serum miRNA profiles can potentially aid in the early diagnosis of pancreatic cancer.
• Identified serum miRNAs may serve as valuable prognostic markers for early-stage PDAC.
• Further research into these miRNA signatures could improve patient outcomes and treatment strategies.